Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma

Journal of Medicinal Chemistry

Volumn 60, Issue 20, 2017, Pages 8466-8481

  Yamada, Ken ^a,b   Brousseau, Margaret ^a   Honma, Wataru ^b   Iimura, Akiko ^b   Imase, Hidetomo ^a,b,c   Iwaki, Yuki ^a,b   Kawanami, Toshio ^a,b   Lasala, Daniel ^a,d   Liang, Guiqing ^a   Mitani, Hironobu ^b   Nonomura, Kazuhiko ^b,e   Ohmori, Osamu ^b,f   Pan, Meihui ^a   Rigel, Dean F ^a,g   Umemura, Ichiro ^b   Yasoshima, Kayo ^a,b   Zhu, Guoming ^a   Mogi, Muneto ^a,b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA K K   (Japan)

^c Janssen Pharmaceutical KK   (Japan)

^d Insmed   (United States)

^e MOCHIDA PHARMACEUTICAL CO   (Japan)

^f ASAHI KASEI PHARMA CORPORATION   (Japan)

^g Rigel BioPharma Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (5 MORPHOLINOPYRIMIDIN 2 YL)AMINO] 2,6 DIETHYLPIPERIDINE 1 CARBONYL]OXY]CYCLOHEXANE 1 CARBOXYLIC ACID; 4 [[4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] [5 (1 METHYL 1H PYRAZOL 4 YL)PYRIMIDIN 2 YL]AMINO] 2,6 DIETHYLPIPERIDINE 1 CARBONYL]OXY]CYCLOHEXANE 1 CARBOXYLIC ACID; ANACETRAPIB; CHIRAL TERT BUTYL 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (5 BROMOPYRIMIDIN 2 YL)AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; CHIRAL TERT BUTYL 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (5 MORPHOLINOPYRIMIDIN 2 YL)AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; ISOPROPYL 2,6 DIETHYL 4 OXOPIPERIDINE 1 CARBOXYLATE; ISOPROPYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (5 MORPHOLINOPYRIMIDIN 2 YL)AMINO] 2,6 DIETHYLPIPERIDINE 1 CARBOXYLATE; PIPERIDINE DERIVATIVE; RAC 1 [2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (5 BROMOPYRIMIDIN 2 YL)AMINO] 6 ETHYLPIPERIDIN 1 YL]BUTAN 1 ONE; RAC 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (5 BROMOPYRIMIDIN 2 YL)AMINO] N,6 DIETHYLPIPERIDINE 1 CARBOXAMIDE; RAC BENZYL 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (METHOXYCARBONYL)AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; RAC BENZYL 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL]AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; RAC BENZYL 2 BENZYL 6 ETHYL 4 OXOPIPERIDINE 1 CARBOXYLATE; RAC ISOPROPYL 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (5 BROMOPYRIMIDIN 2 YL)AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; RAC TERT BUTYL 2 BENZYL 4 [(5 BROMOPYRIMIDIN 2 YL) [3 CHLORO 5 (TRIFLUOROMETHYL)BENZYL]AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; RAC TERT BUTYL 2 BENZYL 4 [(5 BROMOPYRIMIDIN 2 YL) [3 METHOXY 5 (TRIFLUOROMETHYL)BENZYL]AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; RAC TERT BUTYL 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL) BENZYL] (5 METHOXYPYRIMIDIN 2 YL)AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; RAC TERT BUTYL 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL) BENZYL](METHOXYCARBONYL)AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; RAC TERT BUTYL 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (5 BROMOPYRIMIDIN 2 YL)AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; RAC TERT BUTYL 2 BENZYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (5 MORPHOLINOPYRIMIDIN 2 YL)AMINO] 6 ETHYLPIPERIDINE 1 CARBOXYLATE; RAC TERT BUTYL 2 BENZYL 6 ETHYL 4 OXOPIPERIDINE 1 CARBOXYLATE; RAC TERT BUTYL 2 ETHYL 4 OXO 3,4 DIHYDROPYRIDINE 1(2H) CARBOXYLATE; RAC TERT BUTYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (METHOXYCARBONYL)AMINO] 2 ETHYLPIPERIDINE 1 CARBOXYLATE; TERT BUTYL 2,6 DIETHYL 4 OXOPIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL] (METHOXYCARBONYL)AMINO] 2,6 DIETHYLPIPERIDINE 1 CARBOXYLATE; TERT BUTYL 4 [[3,5 BIS(TRIFLUOROMETHYL)BENZYL]AMINO] 2,6 DIETHYLPIPERIDINE 1 CARBOXYLATE; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; CHOLESTEROL ESTER TRANSFER PROTEIN; PIPERIDINE;

ALDOSTERONE RELEASE; ANIMAL EXPERIMENT; ARTICLE; ASYMMETRIC SYNTHESIS; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; ENANTIOMER; EX VIVO STUDY; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; IC50; IN VITRO STUDY; IN VIVO STUDY; IONIZATION; LIMIT OF DETECTION; LIPOPHILICITY; MALE; NONHUMAN; PH; PROTEIN BINDING; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VOLUME OF DISTRIBUTION; X RAY CRYSTALLOGRAPHY; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHICK EMBRYO; MESOCRICETUS;

AGED; ANIMALS; CHICK EMBRYO; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MESOCRICETUS; PIPERIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85032446952     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b00900     Document Type: Article

References (36)

1. Collins, R.; Reith, C.; Emberson, J.; Armitage, J.; Baigent, C.; Blackwell, L.; Blumenthal, R.; Danesh, J.; Smith, G. D.; DeMets, D.; Evans, S.; Law, M.; MacMahon, S.; Martin, S.; Neal, B.; Poulter, N.; Preiss, D.; Ridker, P.; Roberts, I.; Rodgers, A.; Sandercock, P.; Schulz, K.; Sever, P.; Simes, J.; Smeeth, L.; Wald, N.; Yusuf, S.; Peto, R. Interpretation of the evidence for the efficacy and safety of statin therapy Lancet 2016, 388, 2532-2561 10.1016/S0140-6736(16)31357-5
2. Gordon, T.; Castelli, W. P.; Hjortland, M. C.; Kannel, W. B.; Dawber, T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am. J. Med. 1977, 62, 707-714 10.1016/0002-9343(77)90874-9
3. Gordon, D. J.; Probstfield, J. L.; Garrison, R. J.; Neaton, J. D.; Castelli, W. P.; Knoke, J. D.; Jacobs, D. R., Jr.; Bangdiwala, S.; Tyroler, H. A. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 1989, 79, 8-15 10.1161/01.CIR.79.1.8
4. Barter, P. J.; Brewer, H. B., Jr.; Chapman, M. J.; Hennekens, C. H.; Rader, D. J.; Tall, A. R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis Arterioscler., Thromb., Vasc. Biol. 2003, 23, 160-167 10.1161/01.ATV.0000054658.91146.64
5. Thompson, A.; Di Angelantonio, E.; Sarwar, N.; Erqou, S.; Saleheen, D.; Dullaart, R. P.; Keavney, B.; Ye, Z.; Danesh, J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 2008, 299, 2777-2788 10.1001/jama.299.23.2777
6. Johannsen, T. H.; Frikke-Schmidt, R.; Schou, J.; Nordestgaard, B. G.; Tybjaerg-Hansen, A. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects J. Am. Coll. Cardiol. 2012, 60, 2041-2048 10.1016/j.jacc.2012.07.045
7. Barter, P. J.; Caulfield, M.; Eriksson, M.; Grundy, S. M.; Kastelein, J. J.; Komajda, M.; Lopez-Sendon, J.; Mosca, L.; Tardif, J. C.; Waters, D. D.; Shear, C. L.; Revkin, J. H.; Buhr, K. A.; Fisher, M. R.; Tall, A. R.; Brewer, B. Investigators, I. Effects of torcetrapib in patients at high risk for coronary events N. Engl. J. Med. 2007, 357, 2109-2122 10.1056/NEJMoa0706628
8. Forrest, M. J.; Bloomfield, D.; Briscoe, R. J.; Brown, P. N.; Cumiskey, A. M.; Ehrhart, J.; Hershey, J. C.; Keller, W. J.; Ma, X.; McPherson, H. E.; Messina, E.; Peterson, L. B.; Sharif-Rodriguez, W.; Siegl, P. K.; Sinclair, P. J.; Sparrow, C. P.; Stevenson, A. S.; Sun, S. Y.; Tsai, C.; Vargas, H.; Walker, M., 3rd; West, S. H.; White, V.; Woltmann, R. F. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br. J. Pharmacol. 2008, 154, 1465-1473 10.1038/bjp.2008.229
9. Stroes, E. S.; Kastelein, J. J.; Benardeau, A.; Kuhlmann, O.; Blum, D.; Campos, L. A.; Clerc, R. G.; Niesor, E. J. Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats Br. J. Pharmacol. 2009, 158, 1763-1770 10.1111/j.1476-5381.2009.00460.x
10. Hu, X.; Dietz, J. D.; Xia, C.; Knight, D. R.; Loging, W. T.; Smith, A. H.; Yuan, H.; Perry, D. A.; Keiser, J. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 2009, 150, 2211-2219 10.1210/en.2008-1512
11. Johns, D. G.; Duffy, J.; Fisher, T.; Hubbard, B. K.; Forrest, M. J. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors Drugs 2012, 72, 491-507 10.2165/11599310-000000000-00000
12. Schwartz, G. G.; Olsson, A. G.; Abt, M.; Ballantyne, C. M.; Barter, P. J.; Brumm, J.; Chaitman, B. R.; Holme, I. M.; Kallend, D.; Leiter, L. A.; Leitersdorf, E.; McMurray, J. J.; Mundl, H.; Nicholls, S. J.; Shah, P. K.; Tardif, J. C.; Wright, R. S.; dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 2012, 367, 2089-2099 10.1056/NEJMoa1206797
13. Nicholls, S. J.; Lincoff, A. M.; Barter, P. J.; Brewer, H. B.; Fox, K. A.; Gibson, C. M.; Grainger, C.; Menon, V.; Montalescot, G.; Rader, D.; Tall, A. R.; McErlean, E.; Riesmeyer, J.; Vangerow, B.; Ruotolo, G.; Weerakkody, G. J.; Nissen, S. E. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial Am. Heart J. 2015, 170, 1061-1069 10.1016/j.ahj.2015.09.007
14. Barter, P. J.; Rye, K. A. Cholesteryl ester transfer protein inhibition is not yet dead-Pro Arterioscler., Thromb., Vasc. Biol. 2016, 36, 439-441 10.1161/ATVBAHA.115.306879
15. HPS3/TIMI55-REVEAL Collaborative Group Effects of anacetrapib in patients with atherosclerotic vascular disease N. Engl. J. Med. 2017, 377, 1217-1227 10.1056/NEJMoa1706444
16. Liu, S.; Mistry, A.; Reynolds, J. M.; Lloyd, D. B.; Griffor, M. C.; Perry, D. A.; Ruggeri, R. B.; Clark, R. W.; Qiu, X. Crystal structures of cholesteryl ester transfer protein in complex with inhibitors J. Biol. Chem. 2012, 287, 37321-37329 10.1074/jbc.M112.380063
17. Krishna, R.; Garg, A.; Panebianco, D.; Cote, J.; Bergman, A. J.; Van Hoydonck, P.; Laethem, T.; Van Dyck, K.; Chen, J.; Chavez-Eng, C.; Archer, L.; Lutz, R.; Hilliard, D.; Snyder, K.; Jin, B.; Van Bortel, L.; Lasseter, K. C.; Al-Huniti, N.; Dykstra, K.; Gottesdiener, K.; Wagner, J. A. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Br. J. Clin. Pharmacol. 2009, 68, 535-545 10.1111/j.1365-2125.2009.03465.x
18. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890 10.1038/nrd2445
19. Hopkins, A. L.; Keseru, G. M.; Leeson, P. D.; Rees, D. C.; Reynolds, C. H. The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discovery 2014, 13, 105-121 10.1038/nrd4163
20. Kah, M.; Brown, C. D. LogD: lipophilicity for ionisable compounds Chemosphere 2008, 72, 1401-1408 10.1016/j.chemosphere.2008.04.074
21. Hirota, T.; Ieiri, I. Drug-drug interactions that interfere with statin metabolism Expert Opin. Drug Metab. Toxicol. 2015, 11, 1435-1447 10.1517/17425255.2015.1056149
22. Lewis, D. F.; Lake, B. G.; Dickins, M. Quantitative structure-activity relationships (QSars) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding J. Enzyme Inhib. Med. Chem. 2006, 21, 127-132 10.1080/14756360500532747
23. Mogi, M.; Yamada, K.; Yasoshima, K.; Kawanami, T.; Umemura, I.; Iwaki, Y.; Qin, H.; Imase, H. 4-Benzylamino-1-carboxyacyl-piperidine Derivatives as CETP Inhibitors Useful for the Treatment of Diseases Such as Hyperlipidemia or Arteriosclerosis. WIPO PCT WO 2009/059943A1, 2009.
24. Trieselmann, T.; Wagner, H.; Fuchs, K.; Hamprecht, D.; Berta, D.; Cremonesi, P.; Streicher, R.; Luippold, G.; Volz, A.; Markert, M.; Nar, H. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1′-spiro-substituted hexahydrofuroquinoline derivatives J. Med. Chem. 2014, 57, 8766-8776 10.1021/jm500431d
25. Gotto, A. M., Jr.; Cannon, C. P.; Li, X. S.; Vaidya, S.; Kher, U.; Brinton, E. A.; Davidson, M.; Moon, J. E.; Shah, S.; Dansky, H. M.; Mitchel, Y.; Barter, P.; DEFINE Investigators Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease Am. J. Cardiol. 2014, 113, 76-83 10.1016/j.amjcard.2013.08.041
26. Kalgutkar, A. S.; Frederick, K. S.; Hatch, H. L.; Ambler, C. M.; Perry, D. A.; Garigipati, R. S.; Chang, G. C.; Lefker, B. A.; Clark, R. W.; Morehouse, L. A.; Francone, O.; Hu, X. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility Xenobiotica 2014, 44, 591-605 10.3109/00498254.2013.874611
27. Borensztajn, J.; Rone, M. S.; Kotlar, T. J. The inhibition in vivo of lipoprotein lipase (clearing-factor lipase) activity by triton WR-1339 Biochem. J. 1976, 156, 539-543 10.1042/bj1560539
28. Ugawa, T.; Kakuta, H.; Moritani, H.; Inagaki, O.; Shikama, H. YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents Br. J. Pharmacol. 2003, 139, 140-146 10.1038/sj.bjp.0705229
29. Carroll, M. D.; Kit, B. K.; Lacher, D. A.; Shero, S. T.; Mussolino, M. E. Trends in lipids and lipoproteins in US adults, 1988-2010 JAMA 2012, 308, 1545-1554 10.1001/jama.2012.13260
30. Nakamura, K.; Miyoshi, T.; Yunoki, K.; Ito, H. Postprandial hyperlipidemia as a potential residual risk factor J. Cardiol. 2016, 67, 335-339 10.1016/j.jjcc.2015.12.001
31. Wojczynski, M. K.; Parnell, L. D.; Pollin, T. I.; Lai, C. Q.; Feitosa, M. F.; O'Connell, J. R.; Frazier-Wood, A. C.; Gibson, Q.; Aslibekyan, S.; Ryan, K. A.; Province, M. A.; Tiwari, H. K.; Ordovas, J. M.; Shuldiner, A. R.; Arnett, D. K.; Borecki, I. B. Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Metab., Clin. Exp. 2015, 64, 1359-1371 10.1016/j.metabol.2015.07.001
32. Comins, D. L.; Lamunyon, D. H. Preparation of 1-(tert-butoxycarbonyl)-2,6-dialkyl-2,3-dihydro-4-pyridones-a stereocontrolled synthesis of (±)-myrtine Tetrahedron Lett. 1989, 30, 5053-5056 10.1016/S0040-4039(01)93445-8
33. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients. ClinicalTrials.gov; NCT01487460; U.S. National Institutes of Health: Bethesda, MD, 2011; https://clinicaltrials.gov/ct2/show/NCT01487460?term=tap311&rank=1 (accessed Sep 22, 2017).
34. Stiefl, N.; Gedeck, P.; Chin, D.; Hunt, P.; Lindvall, M.; Spiegel, K.; Springer, C.; Biller, S.; Buenemann, C.; Kanazawa, T.; Kato, M.; Lewis, R.; Martin, E.; Polyakov, V.; Tommasi, R.; van Drie, J.; Vash, B.; Whitehead, L.; Xu, Y.; Abagyan, R.; Raush, E.; Totrov, M. FOCUS - Development of a global communication and modeling platform for applied and computational medicinal chemists J. Chem. Inf. Model. 2015, 55, 896-908 10.1021/ci500598e
35. Milletti, F.; Storchi, L.; Sforna, G.; Cruciani, G. New and original pKa prediction method using grid molecular interaction fields J. Chem. Inf. Model. 2007, 47, 2172-2181 10.1021/ci700018y
36. Wasan, K. M.; Cassidy, S. M.; Ramaswamy, M.; Kennedy, A.; Strobel, F. W.; Ng, S. P.; Lee, T. Y. A comparison of step-gradient and sequential density ultracentrifugation and the use of lipoprotein deficient plasma controls in determining the plasma lipoprotein distribution of lipid-associated nystatin and cyclosporine Pharm. Res. 1999, 16, 165-169 10.1023/A:1011951602894